<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094375</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/354/10/19</org_study_id>
    <nct_id>NCT05094375</nct_id>
  </id_info>
  <brief_title>Vaginal Misoprostol In Medical Treatment of First Trimester Missed Miscarriage</brief_title>
  <official_title>Vaginal Misoprostol 600 mcg and 800 mcg In Medical Treatment of First Trimester Missed Miscarriage: A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>hany farouk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of vaginal misoprostol 600 Mg versus 800 Mg in termination of the first trimester&#xD;
      missed abortion were assist&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In women with first trimetric-missed miscarriage, vaginal misoprostol in the achievement of&#xD;
      successful miscarriage so our aim was to compare the effectiveness of vaginal misoprostol 600&#xD;
      Mg versus 800 Mg for medical treatment of the first trimester missed miscarriage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a double-blinded randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>a double-blinded randomized trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Completeness of abortion</measure>
    <time_frame>7 days</time_frame>
    <description>expulsion of Products of conception by visual inspection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful medical abortion</measure>
    <time_frame>14 days</time_frame>
    <description>cervical os is closed with endometrial thickness of less than 15 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding pattern following treatment</measure>
    <time_frame>7 days</time_frame>
    <description>This will be assessed by hemoglobin(g/dl) and haematocrit level after the treatment , if the patients required blood transfusion and number of units transfused and number of days of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain resulting from the procedure</measure>
    <time_frame>7 days</time_frame>
    <description>this will be assessed by the doses of paracetamol given in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional uterotonic used</measure>
    <time_frame>14 days</time_frame>
    <description>additional misoprostol doses in mcg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Miscarriage</condition>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol 600 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.&#xD;
Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).&#xD;
Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.&#xD;
A specimen bottle to collect the POC if passed out.&#xD;
Two pairs of disposable gloves.&#xD;
Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol 800 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.&#xD;
Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).&#xD;
Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.&#xD;
A specimen bottle to collect the POC if passed out.&#xD;
Two pairs of disposable gloves.&#xD;
Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Misoprostol 600 mcg</intervention_name>
    <description>All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.&#xD;
Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).&#xD;
Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.&#xD;
A specimen bottle to collect the POC if passed out.&#xD;
Two pairs of disposable gloves.&#xD;
Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception</description>
    <arm_group_label>Vaginal Misoprostol 600 mcg</arm_group_label>
    <other_name>experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Misoprostol 800 mcg</intervention_name>
    <description>All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.&#xD;
Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).&#xD;
Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.&#xD;
A specimen bottle to collect the POC if passed out.&#xD;
Two pairs of disposable gloves.&#xD;
Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception</description>
    <arm_group_label>Vaginal Misoprostol 800 mcg</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All women above 18 years of age&#xD;
&#xD;
          -  Less than 12 weeks of gestation.&#xD;
&#xD;
          -  Pregnancy is confirmed by pregnancy test or ultrasound scan.&#xD;
&#xD;
          -  missed abortion&#xD;
&#xD;
          -  Normal general and gynecological examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamically unstable.&#xD;
&#xD;
          -  Suspected sepsis with temperature 38 Â°C.&#xD;
&#xD;
          -  Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism,&#xD;
&#xD;
          -  respiratory , recent liver disease, or pruritus of pregnancy.&#xD;
&#xD;
          -  Presence of intrauterine contraceptive device (IUCD).&#xD;
&#xD;
          -  Suspect or proven ectopic pregnancy.&#xD;
&#xD;
          -  Failed medical or surgical evacuation before the presentation.&#xD;
&#xD;
          -  Known allergy to misoprostol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women with missed abortion</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>miscarriage</keyword>
  <keyword>vaginal</keyword>
  <keyword>misoprostol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

